Preview

Supportive Therapy in Oncology

Advanced search

A case of long-term use of denosumab for giant cell tumor of bone

https://doi.org/10.17650/3034-2473-2024-1-3-49-54

Abstract

Giant cell tumor of bone is a locally aggressive primary bone neoplasm affecting patients aged 20–50 years. Neoplastic stromal cells have a phenotype of immature osteoblasts synthesizing various cytokines and molecular factors leading to excessive activation of osteoclastogenesis and increased osteolysis in giant cell tumor of bone. Long-term treatment with denosumab is recommended for unresectable or disseminated disease.

A clinical case of long-term treatment with denosumab of initially generalized giant cell tumor of the right ischial bone with metastases to the lungs is presented. Stabilization of the process was first recorded 3 months after the start of therapy and has been maintained to date. The patient was transferred to a maintenance regimen 3 years after the start of treatment. The treatment was not accompanied by adverse events characteristic of bone-modifying agents.

Long-term use of denosumab allowed effective control of the tumor process and maintenance of satisfactory quality of life of the patient. Maintenance regimen of denosumab administration was not accompanied by a decrease in treatment effectiveness.

About the Authors

L. Yu. Vladimirova
National Medical Research Center for Oncology, Ministry of Health of Russia
Russian Federation

Lyubov Yurievna Vladimirоva

63 14th Liniya St., Rostov-on-Don 344037



N. A. Abramova
National Medical Research Center for Oncology, Ministry of Health of Russia
Russian Federation

63 14th Liniya St., Rostov-on-Don 344037



L. N. Vashchenko
National Medical Research Center for Oncology, Ministry of Health of Russia
Russian Federation

63 14th Liniya St., Rostov-on-Don 344037



A. A. Barashev
National Medical Research Center for Oncology, Ministry of Health of Russia
Russian Federation

63 14th Liniya St., Rostov-on-Don 344037



N. M. Tikhanovskaya
National Medical Research Center for Oncology, Ministry of Health of Russia
Russian Federation

63 14th Liniya St., Rostov-on-Don 344037



References

1. Andrievskikh E.A., Zinoviev G.V., Gafton G.I. et al. Giant cell tumor of bone: a textbook for students. Saint Petersburg: N.N. Petrov National Medical Research Center of Oncology, 2022. 56 p. (In Russ.).

2. Luengo‑Alonso G., Mellado‑Romero M., Shemesh S. et al. Denosumab treatment for giant-cell tumor of bone: a systematic review of the literature. Arch Orthop Trauma Surg 2019;139:1339–49. DOI: 10.1007/s00402-019-03167-x

3. Kito M., Matusmoto S., Tanizawa K. et al. Pulmonary metastasis from giant cell tumor of bone: clinical outcome prior to the introduction of molecular target therapy. Jap J Clin Oncol 2017;6(47):529–34. DOI: 10.1093/jjco/hyx033

4. Yang Y., Huang Z., Niu X. et al. Clinical characteristics and risk factors analysis of lung metastasis of benign giant cell tumor of bone. J Bone Oncol 2017;7:23–8. DOI: 10.1016/j.jbo.2017.04.001

5. Itkin B., Straminsky S., De Ronato G. et al. Prognosis of metastatic giant cell tumor of bone in the pre-denosumab era. A systematic review and a meta-analysis. Jpn J Clin Oncol 2018;48(7):640–52. DOI: 10.1093/jjco/hyy067

6. Gershtein E.S., Timofeev Yu.S., Zuev A.A., Kushlinskiy N.E. RANK/RANKL/OPG ligand-receptor system and its role in primary bone neoplasms (literature analysis and own data). Uspekhi molekulyarnoi onkologii = Advances in Molecular Oncology 2015;(3): 51–9. (In Russ.). DOI: 10.17650/2313-805X.2015.2.3.51-59

7. Valiev A.K., Tararykova A.A., Teplyakov V.V. et al. Practical recommendations for drug treatment of malignant bone tumors. Practical recommendations RUSSCO, part 1. Zlokachestvenniye opukholi = Malignant Tumors 2023;13(3s2):335–55. (In Russ.). DOI: 10.18027/2224-5057-2023-13-3s2-1-335-355

8. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) with NCCN Evidence Blocks™. Version 2.2024. 2024. Available at: https://www.nccn.org/guidelines/guidelines-withevidence-blocks

9. Kajizono M., Sada H., Sugiura Y. et al. Incidence and risk factors of osteonecrosis of the jaw in advanced cancer patients after treatment with zoledronic acid or denosumab: a retrospective cohort study. Biol Pharm Bull 2015;38(12):1850–5. DOI: 10.1248/bpb.b15-00385

10. Nakata E., Kunisada T., Fujiwara T. et al. Efficacy and safety of denosumab de‑escalation in giant cell tumor of bone. Oncol Lett 2024;28(2):387. DOI: 10.3892/ol.2024.14520

11. Schilcher J., Aspenberg P. Atypical fracture of the femur in a patient using Denosumab – a case report. Acta Orthop 2014;85(1):6–7. DOI: 10.3109/17453674.2014.885355

12. Chawla S., Blay J.Y., Rutkowski P. et al. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. Lancet Oncol 2019;20:1719–29. DOI: 10.1016/S1470-2045(19)30663-1

13. Tararykova A.A., Fedenko A.A., Musaev E.R. et al. Safety and effectiveness of continuous denosumab for unresectable or advanced giant cell tumor. Sarkomy kostei myagkikh tkanei i opukholi kozhi = Bone and Soft Tissue Sarcomas, Tumors of the Skin 2023;15(1):57–65. (In Russ.). DOI: 10.17650/2782-3687-2023-15-1-57-65

14. Palmerini E., Chawla N.S., Ferrari S. et al. Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): for how long? Eur J Cancer 2017;76:118–24. DOI: 10.1016/j.ejca.2017.01.028

15. Jiang C.Y., Zhao L., Schuetze S.M., Chugh R. Giant cell tumor of bone: effect of longer dosing intervals of denosumab on tumor control and bone-related complications. Oncologist 2022;27(7):595–9. DOI: 10.1093/oncolo/oyac066


Review

For citations:


Vladimirova L.Yu., Abramova N.A., Vashchenko L.N., Barashev A.A., Tikhanovskaya N.M. A case of long-term use of denosumab for giant cell tumor of bone. Supportive Therapy in Oncology. 2024;1(3):49-54. (In Russ.) https://doi.org/10.17650/3034-2473-2024-1-3-49-54

Views: 64


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 3034-2473 (Print)
ISSN 3034-3178 (Online)